<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NITROFURANTOIN- nitrofurantoin suspension </strong><br>Amneal Pharmaceuticals of New York, LLC<br></p></div>
<h1><span class="Bold">Nitrofurantoin Oral Suspension USP, 25 mg/5 mL</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_d8b0410e-ca29-4a6e-860b-33139b017663"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION </span></h1>
<p class="First">Nitrofurantoin oral suspension, USP, a synthetic chemical, is a stable, yellow, crystalline compound. Nitrofurantoin oral suspension, USP is an antibacterial agent for specific <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Nitrofurantoinoral suspension, USP is available in 25 mg/5 mL liquid suspension for oral administration. </p>
<div class="Figure"><img alt="52ae3bb2-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11dcea9c-0c62-4153-976b-bd1f8ef1f6d9&amp;name=nitrofurantoin-oral-suspension-usp-1.jpg"></div>
<p><span class="Bold">Inactive Ingredients</span></p>
<p>Nitrofurantoin oral suspension, USP contains anhydrous citric acid, artificial fruit flavor, carboxymethylcellulose sodium, glycerin, magnesium aluminum silicate, methylparaben, propylparaben, purified water, saccharin insoluble, sodium citrate, and sorbitol solution</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_1ee644c5-8fb8-4d79-8c89-77d2f525fdaa"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY </span></h1>
<p class="First">Orally administered nitrofurantoin oral suspension is readily absorbed and rapidly excreted in urine. Blood concentrations at therapeutic dosage are usually low. It is highly soluble in urine, to which it may impart a brown color.</p>
<p>Following a dose regimen of 100 mg q.i.d. for 7 days, average urinary drug recoveries (0 to 24 hours) on day 1 and day 7 were 42.7% and 43.6%.</p>
<p>Unlike many drugs, the presence of food or agents delaying gastric emptying can increase the bioavailability of nitrofurantoin oral suspension, presumably by allowing better dissolution in gastric juices.</p>
<p><span class="Bold">Microbiology</span><span class="Bold"> </span></p>
<p><span class="Bold">Mode of Action</span></p>
<p>Nitrofurantoin is reduced by a wide range of enzymes including bacterial flavoproteins to reactive intermediates which are damaging to macromolecules such as DNA and proteins. </p>
<p><span class="Bold">Cross-</span>Resistance</p>
<p>Although cross-resistance with other antimicrobials may occur, cross-resistance with sulfonamides has not been observed. </p>
<p><span class="Bold">Interaction with Other Antimicrobials</span></p>
<p>Antagonism has been demonstrated <span class="Italics">in </span>vitro between nitrofurantoin and quinolone antimicrobial agents. Nitrofurantoin, in the form of nitrofurantoin oral suspension, has been shown to be active against most of the following bacteria both<span class="Italics"> in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: (see <span class="Bold"><a href="#LINK_c5e5fa56-1b47-4098-bc56-cfab56aecba8">INDICATIONS AND USAGE</a></span>). </p>
<p><span class="Bold">Gram-positive Aerobes</span><span class="Bold"> </span></p>
<p><span class="Italics">Staphylococcus aureus</span><span class="Italics"> </span></p>
<p><span class="Italics">Enterococcus species</span></p>
<p><span class="Bold">Gram-Negative Aerobes</span><span class="Bold"> </span></p>
<p><span class="Italics">Escherichia coli</span><span class="Italics"> </span></p>
<p>Note: Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter </span>species and <span class="Italics">Klebsiella</span> species are resistant to nitrofurantoin.</p>
<p>The following <span class="Italics">in </span>vitro data are available, but their clinical significance is unknown. Nitrofurantoin exhibits <span class="Italics">in vitro</span> activity against the following bacteria; however, the safety and effectiveness of nitrofurantoin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well controlled clinical trials. </p>
<p><span class="Bold">Gram-Positive Aerobes</span><span class="Bold"> </span></p>
<p>Coagulase-negative staphylococci (including <span class="Italics">Staphylococcus epidermidis</span> and <span class="Italics">Staphylococcus saprophyticus</span>)</p>
<p><span class="Italics">Streptococcus agalactiae</span><span class="Italics"> </span></p>
<p>Viridans group streptococci </p>
<p><span class="Bold">Gram-Negative Aerobes</span><span class="Bold"> </span></p>
<p><span class="Italics">Citrobacter koseri</span></p>
<p><span class="Italics">Citrobacter freundii</span><span class="Italics"> </span></p>
<p><span class="Italics">Klebsiella oxytoca</span><span class="Italics"> </span></p>
<p>Nitrofurantoin is not active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Proteus</span> species or <span class="Italics">Serratia</span> species. It has no activity against <span class="Italics">Pseudomonas </span>species. </p>
<p><span class="Bold">Susceptibility Test Methods</span><span class="Bold"> </span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<p><span class="Bold">Dilution Techniques</span><span class="Bold"> </span></p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIC"s). These MIC"s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC"s should be determined using a standardized test method<span class="Sup">1,3</span> (broth or agar). The MIC values should be interpreted according to the criteria in Table 1. </p>
<p><span class="Bold">Diffusion Techniques</span><span class="Bold"> </span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility  of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method.<span class="Sup">2</span> This procedure uses paper disks impregnated with 300 mcg of nitrofurantoin to test the susceptibility of bacteria to nitrofurantoin. The disk diffusion interpretive criteria are provided in Table 1. </p>
<p><span class="Bold">Table 1: Susceptibility Interpretive Criteria for Nitrofurantoin</span></p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"> <span class="Bold">Pathogen</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><span class="Bold">Minimum Inhibitory<br>Concentrations (mcg/mL)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"> <span class="Bold">Disk Diffusion Zone<br>Diameter (mm)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">S</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">I</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">R</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">S</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">I</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> <span class="Bold">R</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Italics">Enterobacteriaceae</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> ≤32</td>
<td class="Botrule Lrule Rrule Toprule"> 64</td>
<td class="Botrule Lrule Rrule Toprule"> ≥128</td>
<td class="Botrule Lrule Rrule Toprule"> ≥17</td>
<td class="Botrule Lrule Rrule Toprule"> 15 to 16</td>
<td class="Botrule Lrule Rrule Toprule"> ≤14</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"> <span class="Italics">Staphylococcus aureus</span>
</td>
<td class="Botrule Lrule Rrule Toprule"> ≤32</td>
<td class="Botrule Lrule Rrule Toprule"> 64</td>
<td class="Botrule Lrule Rrule Toprule"> ≥128</td>
<td class="Botrule Lrule Rrule Toprule"> ≥17</td>
<td class="Botrule Lrule Rrule Toprule"> 15 to 16</td>
<td class="Botrule Lrule Rrule Toprule"> ≤14</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"> <span class="Italics">Enterococcus </span>species</td>
<td class="Botrule Lrule Rrule Toprule"> ≤32</td>
<td class="Botrule Lrule Rrule Toprule"> 64</td>
<td class="Botrule Lrule Rrule Toprule"> ≥128</td>
<td class="Botrule Lrule Rrule Toprule"> ≥17</td>
<td class="Botrule Lrule Rrule Toprule"> 15 to 16</td>
<td class="Botrule Lrule Rrule Toprule"> ≤14</td>
</tr>
</tbody>
</table>
<p>S = susceptible, I = intermediate, R = resistant</p>
<p>A report of &amp;apos;Susceptible&amp;apos; indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of &amp;apos;Intermediate&amp;apos; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body site where the drug is physiologically concentrated. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &amp;apos;Resistant&amp;apos; indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected. </p>
<p><span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.<span class="Sup">1,2,3</span> Standard nitrofurantoin powder should provide the following MIC values provided in Table 2. For the diffusion technique using the 300-mcg nitrofurantoin disk the criteria provided in Table 2 should be achieved. </p>
<p><span class="Bold">Table 2: Acceptable Quality Control Ranges for Susceptibility Testing</span></p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"> <span class="Bold">Quality Control Organism</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Minimum Inhibitory<br>Concentrations<br>(mcg/mL)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Disk Diffusion<br>(zone diameters in mm)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Escherichia coli <br></span>(ATCC 25922)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 4 to 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 20 to 25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Staphylococcus aureus <br></span>(ATCC 25923)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> N/A<span class="Sup">a</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 18 to 22</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Staphylococcus aureus <br></span>(ATCC 29213)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 8 to 32</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> N/A<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Streptococcus pneumoniae<br></span>(ATCC 49619)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 4 to 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 23 to 29</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">
<span class="Italics">Enterococcus faecalis<br></span>(ATCC 29212)</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> 4 to 16</td>
<td class="Botrule Lrule Rrule Toprule" align="center"> N/A<span class="Sup">a</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Not Applicable</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_c5e5fa56-1b47-4098-bc56-cfab56aecba8"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS &amp; USAGE </span></h1>
<p class="First">Nitrofurantoin oral suspension, USP is specifically indicated for the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> when due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli, enterococci</span>, <span class="Italics">Staphylococcus aureus</span>, and certain susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Klebsiella </span>and<span class="Italics"> Enterobacter</span> species. </p>
<p>Nitrofurantoin oral suspension, USP is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span> or perinephric <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>. </p>
<p>Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>. Consequently, many patients who are treated with nitrofurantoin oral suspension, USP are predisposed to persistence or reappearance of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span>. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span> occurs after treatment with nitrofurantoin oral suspension, USP, other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin oral suspension, USP, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_d2a5e043-88d2-4773-834f-feaec1e5bf7e"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS </span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug.</p>
<p>Because of the possibility of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age.</p>
<p>Nitrofurantoin oral suspension, USP is contraindicated in patients with a previous history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with nitrofurantoin. Nitrofurantoin oral suspension, USP is also contraindicated in those patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nitrofurantoin, USP. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS </span></h1>
<p class="First"><span class="Bold">Pulmonary reactions</span><span class="Bold"><br></span><span class="Bold">ACUTE, SUBACUTE, OR CHRONIC PULMONARY REACTIONS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH NITROFURANTOIN. IF THESE REACTIONS OCCUR, NITROFURANTOIN ORAL SUSPENSION SHOULD BE DISCONTINUED AND APPROPRIATE MEASURES TAKEN. REPORTS HAVE CITED PULMONARY REACTIONS AS A CONTRIBUTING CAUSE OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. </span></p>
<p><span class="Bold">CHRONIC PULMONARY REACTIONS (DIFFUSE <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">INTERSTITIAL PNEUMONITIS</span> OR <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">PULMONARY FIBROSIS</span>, OR BOTH) CAN DEVELOP INSIDIOUSLY. THESE REACTIONS OCCUR RARELY AND GENERALLY IN PATIENTS RECEIVING THERAPY FOR SIX MONTHS OR LONGER. CLOSE MONITORING OF THE PULMONARY CONDITION OF PATIENTS RECEIVING LONG-TERM THERAPY IS WARRANTED AND REQUIRES THAT THE BENEFITS OF THERAPY BE WEIGHED AGAINST POTENTIAL RISKS (SEE </span><a href="#LINK_7f93f092-f1c1-48bb-b04a-b7b4eb3e583d">RESPIRATORY REACTIONS</a><span class="Bold">). </span></p>
<p><span class="Bold">Hepatotoxicity</span></p>
<p>Hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, occur rarely. Fatalities have been reported. The onset of <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span> may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. If <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occurs, the drug should be withdrawn immediately and appropriate measures should be taken.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="437246" conceptname="Vitamin B deficiency">vitamin B deficiency</span>, and debilitating disease may enhance the occurrence of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p>Patients receiving long-term therapy should be monitored periodically for changes in renal function.</p>
<p><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span> has been reported rarely in postmarketing experience with nitrofurantoin formulations.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span></span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> of the primaquine-sensitivity type have been induced by nitrofurantoin. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients. This deficiency is found in 10 percent of Blacks and a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> is an indication for discontinuing Nitrofurantoin oral suspension; <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> ceases when the drug is withdrawn.</p>
<p><span class="Bold"><span class="Italics">Clostridium difficile</span></span><span class="Bold">-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>:</span></p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including nitrofurantoin oral suspension, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_ad9c3d9a-fee0-4678-a6b1-85a7846cd920"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS </span></h1>
<p class="First"><span class="Bold">Information for Patients </span></p>
<p>Patients should be advised to take nitrofurantoin oral suspension with food to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms should occur during therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p>Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking nitrofurantoin oral suspension<span class="Bold">. </span></p>
<p><span class="Bold">Drug Interactions</span></p>
<p>Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.</p>
<p>Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.</p>
<p><span class="Bold">Drug/Laboratory Test Interactions </span></p>
<p>As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict's and Fehling's solutions but not with the glucose enzymatic test.</p>
<p><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></p>
<p>Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks. Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF<span class="Sup">1</span> mice revealed no evidence of carcinogenicity.</p>
<p>Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F<span class="Sup">1</span> mice as shown by increased incidences of tubular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, benign mixed tumors, and granulosa cell tumors of the ovary. In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcomas</span> of the bone, and neoplasms of the subcutaneous tissue. In one study involving subcutaneous administration of 75 mg/kg nitrofurantoin to pregnant female mice, lung papillary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of unknown significance were observed in the F1 generation.</p>
<p>Nitrofurantoin has been shown to induce point mutations in certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and forward mutations on L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture. Results of the sex-linked recessive lethal assay in Drosophila were negative after administration of nitrofurantoin by feeding or by injection. Nitrofurantoin did not induce heritable mutation in the rodent models examined.</p>
<p>The significance of carcinogenicity and mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown.</p>
<p>The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug. Doses of 10 mg/kg/day or greater in healthy human males may, in certain unpredictable instances, produce a slight to moderate spermatogenic arrest with a decrease in sperm count.</p>
<p><span class="Bold">Pregnancy</span></p>
<p><span class="Bold">Teratogenic effects</span></p>
<p>Pregnancy Category B. Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin. In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> and a low incidence of minor and common malformations were observed. However at 25 times the human dose, <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> were not observed; the relevance of these findings to humans is uncertain. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Bold">Non-teratogenic effects: </span></p>
<p>Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in the F1 generation mice at doses 19 times the human dose on a mg/kg basis. The relationship of this finding to potential human carcinogenesis is presently unknown. Because of the uncertainty regarding the human implications of these animal data, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Bold">Labor and Delivery</span></p>
<p>See <a href="#LINK_d2a5e043-88d2-4773-834f-feaec1e5bf7e">Contraindications</a><span class="Bold">. </span></p>
<p><span class="Bold">Nursing Mothers </span></p>
<p>Nitrofurantoin has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (See <a href="#LINK_d2a5e043-88d2-4773-834f-feaec1e5bf7e">CONTRAINDICATIONS</a>).</p>
<p><span class="Bold">Pediatric Use </span></p>
<p>Safety and effectiveness of nitrofurantoin oral suspension in neonates below the age of one month have not been established (See <a href="#LINK_d2a5e043-88d2-4773-834f-feaec1e5bf7e">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7f93f092-f1c1-48bb-b04a-b7b4eb3e583d"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS </span></h1>
<p class="First"><span class="Bold">Respiratory</span></p>
<p><span class="Bold">CHRONIC, SUBACUTE, OR ACUTE PULMONARY <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY OCCUR. </span></p>
<p><span class="Bold">CHRONIC PULMONARY REACTIONS MAY OCCUR GENERALLY IN PATIENTS WHO HAVE RECEIVED CONTINUOUS TREATMENT FOR SIX MONTHS OR LONGER. <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">MALAISE</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">DYSPNEA</span> ON EXERTION, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">COUGH</span>, AND ALTERED PULMONARY FUNCTION ARE COMMON MANIFESTATIONS WHICH CAN OCCUR INSIDIOUSLY. RADIOLOGIC AND HISTOLOGIC FINDINGS OF DIFFUSE <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">INTERSTITIAL PNEUMONITIS</span> OR <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">FIBROSIS</span>, OR BOTH, ARE ALSO COMMON MANIFESTATIONS OF THE CHRONIC PULMONARY REACTION. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">FEVER</span> IS RARELY PROMINENT. </span></p>
<p><span class="Bold">THE SEVERITY OF CHRONIC PULMONARY REACTIONS AND THEIR DEGREES OF RESOLUTION APPEAR TO BE RELATED TO THE DURATION OF THERAPY AFTER THE FIRST CLINICAL SIGNS APPEAR. PULMONARY FUNCTION MAY BE IMPAIRED PERMANENTLY, EVEN AFTER CESSATION OF THERAPY. THE RISK IS GREATER WHEN CHRONIC PULMONARY REACTIONS ARE NOT RECOGNIZED EARLY. </span></p>
<p>In subacute pulmonary reactions, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> occur less often than in the acute form. Upon cessation of therapy, recovery may require several months. If the symptoms are not recognized as being drug-related and nitrofurantoin therapy is not stopped, the symptoms may become more severe.</p>
<p>Acute pulmonary reactions are commonly manifested by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltration with consolidation of <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> on x-ray, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. Acute reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Resolution often is dramatic (See <a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS</a>).</p>
<p>Changes in EKG (e.g., non-specific ST/T wave changes, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>) have been reported in association with pulmonary reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span> has been reported rarely.</p>
<p><span class="Bold">Hepatic</span></p>
<p>Hepatic reactions, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, and hepatic <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, occur rarely (See <a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS</a>).</p>
<p><span class="Bold">Neurologic </span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="437246" conceptname="Vitamin B deficiency">vitamin B deficiency</span>, and debilitating diseases may increase the possibility of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (See <a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> have also been reported with the use of nitrofurantoin.</p>
<p><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign intracranial hypertension</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> have been reported rarely. Bulging fontanels, as a sign of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in infants, have been reported rarely.</p>
<p><span class="Bold">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) have been reported rarely. Transient <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> also has been reported.</p>
<p><span class="Bold">Allergic</span></p>
<p>A lupus-like syndrome associated with pulmonary reactions to nitrofurantoin has been reported. Also, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; maculopapular, erythematous, or eczematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>; and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> (sometimes associated with pulmonary reactions) have been reported. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> present the most frequent spontaneously-reported adverse events in world-wide postmarketing experience with nitrofurantoin formulations. </p>
<p><span class="Bold">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> occur most often. <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> are less common gastrointestinal reactions. These dose-related reactions can be minimized by reduction of dosage. <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">Sialadenitis</span> and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported. There have been sporadic reports of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> with the use of nitrofurantoin. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antimicrobial treatment (See <a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS</a>).</p>
<p><span class="Bold">Hematologic </span></p>
<p><span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span> secondary to <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> has been reported rarely.</p>
<p><span class="Bold">Miscellaneous</span></p>
<p>As with other antimicrobial agents, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> caused by resistant organisms, e.g., <span class="Italics">Pseudomonas</span> species or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species, can occur. There are sporadic reports of <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span>, or <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, with the use of nitrofurantoin.</p>
<p><span class="Bold">Laboratory Adverse Events</span></p>
<p>The following laboratory adverse events have been reported with the use of nitrofurantoin; increased AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), increased ALT (SGPT), <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, increased serum phosphorus, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, glucose-6-phosphate dehydrogenase <span class="product-label-link" type="condition" conceptid="4280354" conceptname="Nutritional anemia">deficiency anemia</span> (see <span class="Bold"><a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. In most cases, these hematologic abnormalities resolved following cessation of therapy. <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span> has been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_339253a0-0386-492b-ace2-5ecb641f2efe"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Occasional incidents of acute overdosage of nitrofurantoin oral suspension have not resulted in any specific symptoms other than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is recommended. There is no specific antidote, but a high fluid intake should be maintained to promote urinary excretion of the drug. It is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_44cee8b7-8015-4f05-96c5-cbfadc542ddc"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE &amp; ADMINISTRATION </span></h1>
<p class="First">Nitrofurantoin oral suspension, USP should be given with food to improve drug absorption and, in some patients, tolerance.</p>
<p><span class="Bold">Adults </span></p>
<p>50 to 100 mg four times a day - the lower dosage level is recommended for uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
<p><span class="Bold">Pediatric Patients </span></p>
<p>5 to 7 mg/kg of body weight per 24 hours, given in four divided doses (contraindicated under one month of age).</p>
<p>The following table is based on an average weight in each range receiving 5 to 6 mg/kg of body weight per 24 hours, given in four divided doses. It can be used to calculate an average dose of nitrofurantoinoral suspension, USP (25 mg/5 mL) for pediatric patients. </p>
<p><span class="Bold">Table 3: Pediatric Dosing Table</span></p>
<table border="1" cellpadding="0" cellspacing="0">
<col width="2.2in">
<col width="100.55pt">
<tbody class="Headless">
<tr class="First">
<td colspan="2"><p class="First"><span class="Bold">Weight in Kilograms (kg)</span></p></td>
<td class="Lrule"><p class="First"><span class="Bold">Pediatric Doses (milliliters) and Frequency</span></p></td>
</tr>
<tr>
<td class="Lrule Toprule" colspan="2"> <p class="First">7 kg to 11 kg</p>
</td>
<td class="Lrule Toprule"><p class="First">2.5 mL Four times Daily</p></td>
</tr>
<tr>
<td class="Lrule Toprule" colspan="2"> <p class="First">12 kg to 21 kg</p>
</td>
<td class="Lrule Toprule"><p class="First">5 mL Four times Daily</p></td>
</tr>
<tr>
<td class="Lrule Toprule" colspan="2"><p class="First"> 22 kg to 30 kg</p></td>
<td class="Lrule Toprule"><p class="First">7.5 mL Four times Daily</p></td>
</tr>
<tr>
<td class="Lrule Toprule" colspan="2"><p class="First"> 31 kg to 41 kg</p></td>
<td class="Lrule Toprule"><p class="First">10 mL Four times Daily</p></td>
</tr>
<tr class="Last">
<td class="Lrule Toprule" colspan="2"><p class="First">42 kg or greater</p></td>
<td class="Lrule Toprule"><p class="First">See Adult Dose</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"> </span></p>
<p> Therapy should be continued for one week or for at least 3 days after <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the urine is obtained. Continued <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> indicates the need for reevaluation.</p>
<p>For long-term suppressive therapy in adults, a reduction of dosage to 50 to 100 mg at bedtime may be adequate. For long-term suppressive therapy in pediatric patients, doses as low as 1 mg/kg per 24 hours, given in a single dose or in two divided doses, may be adequate. <span class="Bold">SEE </span><span class="Bold"><a href="#LINK_4a52df9d-4dca-4b5b-a8c1-f34a46baf356">WARNINGS SECTION REGARDING RISKS ASSOCIATED WITH LONG TERM THERAPY</a></span><span class="Bold">. </span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_3580855a-2661-4b77-bf84-24e0b6de5cc1"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First">Nitrofurantoin oral suspension, USP (a clear, yellow colored, tutti fruity flavored suspension) containing 25 mg nitrofurantoin, USP in each teaspoonful (5 mL) is available as follows:</p>
<p>230 mL in an 8 oz amber bottle. </p>
<p><span class="Bold">NDC</span> 65162-689-88 </p>
<p>Avoid exposure to strong light which may darken the drug. It is stable when stored between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from freezing. Shake vigorously. Dispense in tight, light-resistant, amber glass bottles. Use within 30 days.</p>
<p>Keep out of reach of children. </p>
<p><span class="Bold">Rx only. </span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_76436373-73b8-4081-ae54-b910beabf4b8"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<p class="First">1. Clinical and Laboratory Standards Institute (CLSI)<span class="Italics">. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;</span><span class="Italics">Approved Standard-Ninth Edition.</span> CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA,2012. </p>
<p>2. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests;</span><span class="Italics">Approved Standard-Eleventh Edition. </span> CLSI document M02-A11. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012. </p>
<p>3. Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing;</span><span class="Italics">Twenty-third Informational Supplement,</span> CLSI document M100-S23. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.</p>
<p>Manufactured by:<br><span class="Bold">Amneal Pharmaceuticals<br></span>Branchburg, NJ 08876</p>
<p>Distributed by:<br><span class="Bold">Amneal Pharmaceuticals<br></span>Glasgow, KY 42141</p>
<p>Rev. 07-2014-00</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_2cff1223-a5da-49e0-999e-359d0edde697"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<p class="First"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11dcea9c-0c62-4153-976b-bd1f8ef1f6d9&amp;name=nitrofurantoin-oral-suspension-usp-2.jpg"> </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_cf2ae8ed-a043-4e64-8124-d71171f3ae87"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=11dcea9c-0c62-4153-976b-bd1f8ef1f6d9&amp;name=nitrofurantoin-oral-suspension-usp-3.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NITROFURANTOIN 		
					</strong><br><span class="contentTableReg">nitrofurantoin suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65162-689</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NITROFURANTOIN</strong> (NITROFURANTOIN) </td>
<td class="formItem">NITROFURANTOIN</td>
<td class="formItem">25 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (Clear) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65162-689-88</td>
<td class="formItem">230 mL in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201679</td>
<td class="formItem">03/24/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Amneal Pharmaceuticals of New York, LLC
							(123797875)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Amneal Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">963900878</td>
<td class="formItem">ANALYSIS(65162-689), LABEL(65162-689), MANUFACTURE(65162-689), PACK(65162-689)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6ba01cf7-c86f-46dd-b4f2-d639a356fc57</div>
<div>Set id: 11dcea9c-0c62-4153-976b-bd1f8ef1f6d9</div>
<div>Version: 6</div>
<div>Effective Time: 20150116</div>
</div>
</div> <div class="DistributorName">Amneal Pharmaceuticals of New York, LLC</div></p>
</body></html>
